PTC Therapeutics (South Plainfield, NJ) a clinical-stage small molecule company focused on CF, hemophilia and muscular dystrophy, closed a $50M Series E financing. Participants include The Column Group, Delphi Ventures, CSFB Private Equity, HBM BioVentures and Novo Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Ophthotech (Princeton, NJ) a clinical-stage biopharmaceutical company focused on ophthalmic therapies for wet and dry age-related macular degeneration, closed a $30M Series B financing. Participants include Clarus Ventures, SV Life Sciences, Novo Ventures and HBM BioVentures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Probiodrug (Germany) a clinical-stage small molecule biopharmaceutical company focused upon Alzheimer’s and inflammation diseases, closed a $54M Series B financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Science Partners, Biogen Idec New Ventures, HBM Bioventures and TVM Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

MTM Laboratories (Germany) a commercial-stage molecular diagnostics company focused on cervical cancer, closed on an $10M bringing the Series C financing to $56M. Participants includeGilde Healthcare Partners , LBBW Venture Capital, HBM BioVentures, and HBM BioCapital.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Lux Biosciences (Jersey City, NJ) a clinical-stage biotechnology company focused on ophthalmic diseases, closed a $50M Series B financing. Participants include HBM Bioventures, De Novo Ventures, Prospect Venture Partners, SV Life Sciences and International Biotechnology Trust.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.